101. Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma.
- Author
-
Corrias MV, Parodi S, Haupt R, Lacitignola L, Negri F, Sementa AR, Dau D, Scuderi F, Carlini B, Bianchi M, Casale F, Faulkner L, and Garaventa A
- Subjects
- Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism, Biopsy, Needle, Child, Child, Preschool, Female, Gene Amplification, Genes, myc, Humans, Infant, Infant, Newborn, Male, N-Acetylgalactosaminyltransferases analysis, Neuroblastoma metabolism, Neuroblastoma pathology, Prognosis, Survival Analysis, Bone Marrow Cells metabolism, N-Acetylgalactosaminyltransferases metabolism, Neuroblastoma diagnosis, Neuroblastoma mortality
- Abstract
The impact of bone marrow (BM) GD2-positive cells on survival has been evaluated in 145 Italian children with localised neuroblastoma (NB) evaluated at diagnosis by anti-GD2 immunocytochemistry. Nineteen of these (13.1%) were found to be BM GD2-positive, with the number of positive cells ranging between 1 and 155 out of 1 x 10(6) total cells analysed. Seven/19 (38.8%) GD2-positive vs 12/126 (9.5%) GD2-negative patients relapsed. The 5-year event-free survival (EFS) and overall survival of the GD2-positive patients was significantly worse than that of the GD2-negative ones (62.2 vs 89.9%, P<0.001; and 74.9 vs 95.9%, P=0.005, respectively). GD2 positivity was not associated to other known risk factors, and in particular to Myc-N amplification and 1p deletion. Among Myc-N-negative patients, the EFS of those negative for both GD2 and 1p deletion was significantly better than in children positive for either one of these two markers (EFS=96.9 vs 66.0%, P<0.001). In conclusion, GD2 positivity may represent a prognostic marker for patients with non-metastatic NB without Myc-N amplification, and its combination with genetic alterations might help identifying patients that require a more careful follow-up.
- Published
- 2008
- Full Text
- View/download PDF